Improving Clinical Management and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis in China via Real-world Evidence (IMPROVE Study): A Multicenter Prospective Cohort Study

被引：0

作者：

Nan Jiang ^{[1
]}

Dongzhou Liu ^{[2
]}

Xinwang Duan ^{[3
]}

Lijun Wu ^{[4
]}

Yi Liu ^{[5
]}

Hao Zhu ^{[6
]}

Yanjie Zhang ^{[7
]}

Mengtao Li ^{[8
]}

Xinping Tian ^{[9
]}

Xiaofeng Zeng ^{[10
]}

机构：

[1] Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing

[2] National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing

[3] State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing

[4] Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing

[5] Department of Rheumatology and Immunology, Shenzhen People’s Hospital, The Second Clinical Medical College, Jinan University, Guangdong, Shenzhen

[6] The First Affiliated Hospital, Southern University of Science and Technology, Guangdong, Shenzhen

[7] Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang

[8] Department of Rheumatology, Xinjiang Uygur Autonomous Region People’s Hospital, Xinjiang Uygur Autonomous Region, Urumuqi

[9] Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Sichuan, Chengdu

[10] Eli Lilly China, Jiangsu, Suzhou

来源：

Advances in Therapy | 2025年 / 42卷 / 6期

关键词：

Disease activity; Disease management; Improvement; Patient-reported outcomes; Rheumatoid arthritis;

D O I：

10.1007/s12325-025-03179-7

中图分类号：

学科分类号：

摘要：

Introduction: Patient-reported outcomes (PROs) help to understand rheumatoid arthritis (RA) from patients’ perspective and play an important role in RA management. This study aims to describe the PRO changes over 6 months among patients with RA in China and explore the relationships between PROs and RA disease activity. Methods: This multicenter prospective cohort study enrolled patients with RA aged ≥ 18 years. At enrollment, patients were dichotomized into remission/low disease activity (LDA) and moderate-to-high disease activity (MDA/HDA) based on Disease Activity Score-28 with C-Reactive Protein (DAS28-CRP). Only patients with MDA/HDA (DAS28-CRP ≥ 3.2) were followed for 6 months. PROs included pain, fatigue, morning stiffness, Patients’ Global Assessment (PtGA), disability, work productivity, and activity impairment. Disease activity measures included DAS28-CRP, DAS28-Erythrocyte Sedimentation Rate (DAS28-ESR), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI). Results: A total of 872 patients were enrolled: 520 patients in remission/LDA and 352 in MDA/HDA. In MDA/HDA patients, pain decreased significantly from enrollment at month 1 (p < 0.0001), month 3 (p < 0.0001), and month 6 (p = 0.0094). Fatigue improved significantly at month 3 (p = 0.0073). Other PROs, including morning stiffness, PtGA, disability, work productivity, and activity impairment, also improved. Patients who achieved remission/LDA had significant faster decline in pain, fatigue, PtGA, and work productivity compared to those who did not. Pain was positively correlated with disease activity measures at months 1, 3, and 6, while fatigue was positively associated with disease activity measures at months 3 and 6 only. Morning stiffness, PtGA, and disability correlated with disease activity at months 1 and 3. Conclusions: Patients with RA with MDA/HDA in China experienced significant improvement in pain and fatigue over 6 months. Improvement in DAS28-CRP was associated with faster improvement in certain PROs. While disease activity correlated with some PROs, they did not fully capture patient experience, highlighting the importance of PROs in RA management. © The Author(s) 2025.

引用

页码：2906 / 2921

页数：15

共 43 条

[1]

Pisetsky D.S., Pathogenesis of autoimmune disease, Nat Rev Nephrol, 19, 8, pp. 509-524, (2023)

[2]

Black R.J., Cross M., Haile L.M., Culbreth G.T., Steinmetz J.D., Hagins H., Et al., Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021, Lancet Rheumatol, 5, 10, pp. e594-e610, (2023)

[3]

Jin S., Li M., Fang Y., Li Q., Liu J., Duan X., Et al., Chinese Registry of rheumatoid arthritis (CREDIT): II. Prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis, Arthritis Res Ther, 19, (2017)

[4]

Pelechas E., Kaltsonoudis E., Voulgari P.V., Drosos A.A., Rheumatoid arthritis, Illustrated handbook of rheumatic and musculo-skeletal diseases, pp. 45-76, (2019)

[5]

van Vilsteren M., Boot C.R., Knol D.L., van Schaardenburg D., Voskuyl A.E., Steenbeek R., Et al., Productivity at work and quality of life in patients with rheumatoid arthritis, BMC Musculoskelet Disord, 16, (2015)

[6]

Malm K., Bergman S., Andersson M.L., Bremander A., Larsson I., Quality of life in patients with established rheumatoid arthritis: a phenomenographic study, SAGE Open Med, 5, (2017)

[7]

Gettings L., Psychological well-being in rheumatoid arthritis: a review of the literature, Musculoskelet Care, 8, 2, pp. 99-106, (2010)

[8]

Smolen J.S., Aletaha D., Bijlsma J.W.J., Breedveld F.C., Boumpas D., Burmester G., Et al., Treating rheumatoid arthritis to target: recommendations of an international task force, Ann Rheum Dis, 69, 4, pp. 631-637, (2010)

[9]

Smolen J.S., Breedveld F.C., Burmester G.R., Bykerk V., Dougados M., Emery P., Et al., Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force, Ann Rheum Dis, 75, 1, pp. 3-15, (2016)

[10]

Aletaha D., Landewe R., Karonitsch T., Bathon J., Boers M., Bombardier C., Et al., Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations, Ann Rheum Dis, 67, 10, pp. 1360-1364, (2008)

← 1 2 3 4 5 →